Bristol Myers Squibb said a pivotal Phase 2 study of its GPRC5D-directed CAR-T cell therapy hit its primary endpoint. The company’s update extends BMS’s efforts to compete for the post-BCMA multiple myeloma market as CAR-T and other immune cell therapies expand beyond the first-line setting. The program targets GPRC5D, a different surface antigen approach compared with established BCMA-directed strategies, aiming to address patients whose disease progresses after prior CAR-T exposure or standard therapies. A Phase 2 “primary endpoint met” signal is likely to draw attention from both partners and competitors as trial design and regulatory strategy for next-generation myeloma CAR-Ts become more aggressive.